P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012 Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Antonia, S
  • Gettinger, S
  • Borghaei, H
  • Goldman, JW
  • Brahmer, J
  • Ready, N
  • Gerber, D
  • Chow, L
  • Juergens, Rosalyn
  • Laurie, S
  • Shepherd, F
  • Li, X
  • Li, A
  • Geese, W
  • Hellmann, M

publication date

  • October 2018